AVEO Pharmaceuticals (STU:VPA1) Treasury Stock : €0.00 Mil (As of Sep. 2022)

View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. AVEO Pharmaceuticals's treasury stock for the quarter that ended in Sep. 2022 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

AVEO Pharmaceuticals Treasury Stock Historical Data

The historical data trend for AVEO Pharmaceuticals's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Treasury Stock Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Treasury Stock

Get a 7-Day Free Trial

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

AVEO Pharmaceuticals Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

AVEO Pharmaceuticals (STU:VPA1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines